EcoDrugPlus

Serine/threonine-Protein Phosphatase 2b Catalytic Subunit Alpha Isoform

Ensembl ID : ENSTRUG00000026958
Gene Symbol: LOC101073266
2 Cross references
233 Possible Orthologues:

Serpin Family C Member 1

Ensembl ID : ENSTRUG00000010570
Gene Symbol: SERPINC1
3 Cross references
199 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSTRUG00000022000
Gene Symbol: LOC101063869
2 Cross references
354 Possible Orthologues:

Serum Amyloid P-Component-Like

Ensembl ID : ENSTRUG00000032882
Gene Symbol: LOC101074263
2 Cross references
405 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSTRUG00000012836
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSTRUG00000024592
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSTRUG00000017974
Gene Symbol: SIRT1
4 Cross references
156 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSTRUG00000016137
Gene Symbol: SMO
4 Cross references
204 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSTRUG00000026593
Gene Symbol: SCN5LAB
1 Cross references
251 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSTRUG00000005719
Gene Symbol: SCN12AA
1 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSTRUG00000015715
Gene Symbol: SCN8A
1 Cross references
215 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1-Like

Ensembl ID : ENSTRUG00000005690
Gene Symbol: LOC101061552
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).